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OBJECTIVES We sought to assess the relative therapeutic efficacy of propranolol, nadolol and placebo in
recurrent vasovagal syncope (VVS).
BACKGROUND Central and peripheral mechanisms have been implicated in the pathogenesis of VVS.
Propranolol, nadolol and placebo have different sites of action on central and/or peripheral
mechanisms. It has not yet been clarified whether one of the aforementioned treatments is
more efficient than the others in reducing clinical episodes and exerting a beneficial effect on
patients’ well-being.
METHODS We studied 30 consecutive patients with recurrent VVS and a positive head-up tilt test. All
were serially and randomly assigned to propranolol, nadolol or placebo. Therapy with each
drug lasted three months. On the day of drug crossover, patients reported the total number
of syncopal and presyncopal attacks during the previous period. They also gave a general
assessment of their quality of life, taking into account: 1) symptom recurrence; 2) drug side
effects; and 3) their personal well-being during therapy (scale 0 to 4: 0  very bad/
discontinuation; 1  bad; 2  good; 3  very good; 4  excellent). At the end of the
nine-month follow-up period, they reported whether they preferred a specific treatment over
the others.
RESULTS Spontaneous syncopal and presyncopal episode recurrence during each three-month
follow-up period was reduced by all drugs tested (analysis of variance [ANOVA]: chi-square
 67.4, p  0.0001 for syncopal attacks; chi-square  60.1, p  0.0001 for presyncopal
attacks) No differences were observed in the recurrence of syncope and presyncope among the
three drugs. All drugs improved the patients’ well-being (ANOVA: chi-square  61.9, p 
0.0001).
CONCLUSIONS Propranolol, nadolol and placebo are equally effective treatments in VVS, as demonstrated by
a reduction in the recurrence of syncope and presyncope, as well as an improvement in the
patients’ well-being. (J Am Coll Cardiol 2002;40:499–504) © 2002 by the American
College of Cardiology Foundation
Vasovagal syncope (VVS) is a common disorder of auto-
nomic cardiovascular regulation. It is generally considered to
result from a paradoxical reflex initiated when ventricular
preload is reduced by excessive venous pooling. Central
mechanisms are also important (1–3). The drug class most
widely used for VVS is beta-blockers (4–13). These drugs
exert their effects by multiple mechanisms. Some of them
are mediated through peripheral pathways, whereas others
are mediated through central nervous system pathways; for
example, propranolol, which enters the blood-brain barrier,
has been shown to act not only by blocking beta1- and
beta2-adrenergic receptors, but also by decreasing serotonin
levels in cerebrospinal fluid (14), and it is believed that its
antihypertensive properties are partially exerted by blocking
central nervous system pathways (15,16). In VVS, it has
never been systematically tested whether a high brain
penetration by a lipid-soluble, noncardioselective beta-
blocker, such as propranolol, might add to the therapeutic
efficacy of beta-blockade, relative to that obtained with
nadolol, a beta-blocker with properties similar to propran-
olol in all aspects, except lipid solubility (nadolol does not
enter the blood-brain barrier). It should be noted that, up to
now, only a few randomized, placebo-controlled studies
have assessed the efficacy of beta-blockers in VVS (17–19).
No randomized, blinded, crossover study has been con-
ducted to confirm the efficacy of lipophilic beta-blockers
versus hydrophilic beta-blockers versus placebo. The value
of a placebo arm in such a study is important, as it addresses
the clinical importance of cortical brain inputs in the
pathogenesis of VVS. In addition, the patients’ well-being
during therapy for this syndrome, which most of the time
is not life-threatening, has been a rather underestimated
issue (20). The aim of this study was to test in patients
with recurrent VVS whether one of the treatments—
propranolol, nadolol or placebo—is more efficient than
the others in terms of reducing syncopal and presyncopal
attacks, as well as exerting a beneficial effect on the
patients’ well being.
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METHODS
Study group. Thirty consecutive patients with recurrent
VVS were studied (13 men and 17 women; mean [SE]
age 41  3 years). Inclusion criteria comprised a typical
history of recurrent VVS (at least two syncopal episodes
within the preceding three months) and a positive diagnos-
tic head-up tilt test response on the day the patients were
enrolled. All patients had a clinical cardiologic examination
within normal limits and a normal 12-lead electrocardio-
gram (ECG). As appropriate, patients also had a negative
neurologic, echocardiographic and cardiac electrophysi-
ologic study, as well as an exercise ECG negative for
ischemia. Patients with a definitive history or clinical
suspicion of autonomic failure (i.e., diabetes mellitus or
renal impairment), arterial hypertension, chronic obstructive
airway disease or peripheral vascular disease were not
included in the study. The mean duration of symptoms
before study inclusion was 72  50 months, and the mean
number of syncopal and presyncopal episodes during the
three months preceding study inclusion was 3.4  0.4 and
9.1  1.1, respectively.
Tilt test protocol. Tilt tests were performed between 9 and
11 AM after fasting since midnight, in a quiet room. A
venous cannula was inserted into an antecubital vein, and all
subjects rested in the supine position for 30 min. They were
connected to a continuous ECG monitor and an automatic
arterial blood pressure sphygmomanometer. After baseline
measures of heart rate and arterial blood pressure were
obtained, all subjects were tilted head-up at 60° on an
electrically driven table with a foot-plate support, according
to the protocol previously described (21). The development
of syncope or presyncope, associated with systolic arterial
hypotension (80 mm Hg), with or without bradycardia or
asystole, was considered a positive response. The subtypes of
VVS were classified according to the criteria proposed by
the Vasovagal Syncope International Study (22) investiga-
tors. If a positive response occurred during the initial
upright tilt, the patients were returned to the supine
position and the test was terminated. If 30 min of the
passive tilt test was completed without a positive response,
the patients were returned to the supine position for 10 min,
and then the upright tilt was repeated for 15 min, with
intravenous infusion of isoproterenol (initial infusion rate of
2 g/min, increased by 1 g/min each minute until the
heart rate reached 130 beats/min or until a maximal infusion
rate of 5 g/min).
Study protocol. Patients were reassured about the benign
nature of their syndrome. They gave written, informed
consent to enter the study. The study protocol was approved
by the institutional ethics committee. Patients were ran-
domized to one of the six serial drug combinations (pro-
pranolol/nadolol/placebo; propranolol/placebo/nadolol;
nadolol/propranolol/placebo; nadolol/placebo/propranolol;
placebo/propranolol/nadolol; or placebo/nadolol/
propranolol). Propranolol was given at a dose of 20 to 40 mg
three times a day; nadolol at 40 to 80 mg/day; and placebo
drug at 1 capsule per day. For each patient, the beta-blocker
was administered at the maximally tolerated dose. The
subjects were informed that the number of daily doses of
each drug has nothing to do with its efficacy, but is purely a
matter of pharmacokinetics. Therapy with each drug lasted
three months. At the end of each three-month interval, the
patients were asked: 1) to report the total number of
syncopal and presyncopal episodes during this period; and 2)
to give a general assessment of their quality of life, as
modified by each drug, taking into account symptom
recurrence, drug side effects and their personal well-being
during therapy (scale 0 to 4: 0  very bad/discontinuation;
1  bad; 2  good; 3  very good; 4  excellent). A
repeated tilt test was performed at the end of each three-
month period. After each tilt test, drug crossover was
performed. Patients had no knowledge of the treatment
assigned. At the end of the nine-month follow-up period,
they were asked to report whether they preferred a specific
treatment over the others.
Statistical analysis. Data were analyzed by nonparametric,
repeated measures analysis of variance (ANOVA) (Fried-
man test, STATISTICA, version 6.0). The chi-square test
with Yate’s correction was used as a test of significance for
categorical frequency data. A p value of 0.05 was consid-
ered statistically significant.
RESULTS
One patient discontinued propranolol because of fatigue.
The rest heart rate, number and type of positive tilt test
responses at diagnosis and after each drug treatment are
shown in Table 1. The rest heart rate, assessed at the end of
each three-month period, was reduced to the same extent by
propranolol and nadolol administration. During placebo
administration, a trend toward increased positive, repeated
Abbreviations and Acronyms
ANOVA  analysis of variance
ECG  electrocardiogram/electrocardiographic
VVS  vasovagal syncope
Table 1. Rest Heart Rate and Number and Type of Positive
Tilt Test Responses at Diagnosis and After Each
Drug Treatment
Baseline Propranolol Nadolol Placebo
Rest heart rate
(beats/min)*
65  3 47  2 45  2 60  3
Positive tilt test (n) 30/30 5/30 4/30 10/30
Type of syncope (n)
Mixed 14 5 3 7
Cardioinhibitory 11 0 1 1
Vasodepressive 5 0 0 2
No. of positive tilt tests
with isoproterenol
infusion
13 4 4 9
*Mean value  SE.
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tilt test results was observed, as compared with the other
two drugs tested (p  0.1 vs. nadolol and p  0.2 vs.
propranolol), but did not reach statistical significance.
Spontaneous syncope and presyncope during follow-up.
Spontaneous syncopal and presyncopal episode recurrence
during each three-month follow-up period was reduced by
all drugs tested (ANOVA: chi-square  67.4, p  0.0001
for syncopal attacks; chi-square  60.1, p  0.0001 for
presyncopal attacks). The study patients’ mean  SE
numbers of syncopal and presyncopal episodes are shown
schematically in Figures 1 and 2. No difference was observed
between the drugs regarding the frequency of syncopal and
presyncopal episodes.
Clinical episodes and repeated tilt test results.
Interestingly enough, significant reductions in syncopal and
presyncopal episodes were observed not only in patients
whose tilt test became negative with each treatment, but
also in those who had positive repeated tilt test results with
propranolol (ANOVA: chi-square  5.0, p  0.02 for
syncopal episodes; chi-square  5.0, p  0.02 for presyn-
copal attacks), nadolol (ANOVA: chi-square  4.0, p 
0.04 for syncopal; chi-square  4.0, p  0.04 for presyn-
Figure 1. Mean (SE) number of syncopal episodes before and during therapy with propranolol, nadolol and placebo.
Figure 2. Mean (SE) number of presyncopal episodes before and during therapy with propranolol, nadolol and placebo.
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copal episodes) and placebo treatment (ANOVA: chi-
square  5.4, p  0.02 for syncopal episodes; chi-square 
10.0, p  0.001 for presyncopal episodes). Based on this,
repeated tilt test results were not representative of the
patients’ clinical improvement.
Drug side effects and patients’ well-being. All drugs
improved the patients’ well-being (ANOVA: chi-square 
61.9, p  0.0001). The mean  SE values of the personal
well-being score before therapy and during therapy with
each drug are presented schematically in Figure 3. During
propranolol treatment, five patients were not fully satisfied
due to central side effects (fatigue), whereas three reported a
feeling of “no drug” treatment while taking the placebo.
One patient discontinued propranolol. Four patients re-
ported to prefer nadolol treatment over the others, two
preferred placebo and three preferred propranolol. The
majority of them (70%) were equally satisfied with the three
drugs tested, regarding not only their therapeutic efficacy
but also the lack of clinically important side effects and a
general self-assessment of well-being during therapy.
DISCUSSION
Main findings. In the present study, we found that li-
pophilic beta-blockers, hydrophilic beta-blockers and pla-
cebo drug are equally effective in treating patients with
recurrent VVS. All cause a significant decrease in syncopal
and presyncopal episodes and an improvement in the
patients’ well-being, although occasional personal prefer-
ences have been reported.
Therapy. Recurrent VVS can be a severely disabling dis-
order. Therapy of this syndrome has largely been empiric,
based on the mechanisms that are currently believed to be
the cause of vasovagal fainting. Although central as well as
peripheral mechanisms are important in vasovagal patho-
genesis, their relative contribution has not been fully eluci-
dated.
Our present observation—that is, crossing the blood-
brain barrier by beta-blockers does not add to their thera-
peutic efficacy—is in keeping with previous experimental
reports in rats, in which the vasovagal reaction could be
blocked by beta-blockers, independent of the drug’s ability
to penetrate the central nervous system (23). A similar
therapeutic efficacy between lipid- and water-soluble com-
ponents tested might be due to the fact that central
mechanisms acted upon by propranolol do not add signifi-
cantly to the therapeutic potential of beta-blockers in VVS.
Hence, it seems that the peripheral mechanisms acted upon
by nadolol, as well as by propranolol, are more clinically
important than the central mechanisms influenced by pro-
pranolol alone.
Although beta-blockers have been the most widely used
drug class in the treatment of VVS, up to now, to the best
of our knowledge, only three randomized placebo-
controlled studies assessing the therapeutic efficacy of a
hydrophilic, cardioselective beta-blocker (atenolol) have
been published. In the first study (17), patients with VVS
were randomized to six-week treatment with atenolol,
scopolamine, clonidine and placebo. Atenolol was not
superior to the placebo treatment in preventing VVS during
repeated tilt testing; moreover, a comparison of the time to
syncope in positive tilt tests during treatment with atenolol
or placebo showed that syncope occurred earlier with
atenolol. In the second study (18), patients with VVS were
randomized to atenolol or placebo, and a repeated tilt test
was performed one month later. A significantly higher
response rate was found in the atenolol group. A similar
Figure 3. Patients’ self-assessed well-being before and during therapy with propranolol, nadolol and placebo.
502 Flevari et al. JACC Vol. 40, No. 3, 2002
Drug Therapy in VVS August 7, 2002:499–504
trend regarding repeated tilt test results was observed in our
study patients. Nevertheless, the clinical response to treat-
ment was the same between beta-blockade and placebo
treatment. The clinical response to treatment seems to be
more important than repeated tilt test results, because the
value of the head-up tilt test for assessing therapeutic
interventions has already been questioned by previous in-
vestigators (12,24–27). Our study patients with positive
repeated tilt test results (under each drug treatment tested)
also showed important clinical improvement. The results of
the third published randomized, controlled study are also in
keeping with our findings: Madrid et al. (19) recently found
that the recurrence of neurocardiogenic syncope in patients
treated with atenolol is similar to that of patients treated
with placebo.
The value of a placebo arm in a study testing the
therapeutic efficacy in VVS can assess the contribution of
the brain cortex in the pathogenesis of VVS. It is important
to note that most previous placebo-controlled studies of
VVS (17,19,28–34) also found that placebo treatment is
equally effective as the other treatments tested. Its effective-
ness may be due to the fact that cortical inputs may interface
into the hypothalamus and other places in the brain to either
potentiate or eliminate an afferent cardiac or noncardiac
input. Cortical inputs may also replace or mimic cardiac or
peripheral afferent signals and thus introduce or not intro-
duce a vagal reaction. In this respect, reassuring the patient
about the benign nature of the syndrome and placebo
administration seems to be helpful in reducing episodes. It
is possible that simply reassuring patients may be of impor-
tant clinical value, but this has not yet been systematically
tested. So far, the importance of the central nervous system
has been traditionally associated with the so-called “central”
type of neurally mediated syncope (linked to strong emo-
tional stimulation, such as that occurring in patients with
blood or injury phobia) (1,35), but not with the “postural”
type (associated with standing) of neurally mediated syn-
cope. As we have observed, it is possible that the role of the
central nervous system, as acted upon by placebo adminis-
tration (and possibly by reassuring the patient), is more
important than previously thought. An interesting nonphar-
macologic therapy for neurocardiogenic syncope—tilt train-
ing—has been proposed (36,37). The investigators report
that one of the possible mechanisms of symptom improve-
ment may be related to a powerful, positive psychological
impact on patients who often suffer a severe psychological
burden. Another important issue in VVS is that patients
with multiple vasovagal episodes are more likely to have
psychiatric disorders, such as somatization, panic, general-
ized anxiety and depression (38), which can sometimes be
undiagnosed. It is possible that in some patients with VVS,
a sporadic first syncopal episode (otherwise not requiring
diagnostic or therapeutic intervention) may lead to recur-
rences through psychological/psychopathologic mecha-
nisms, usually accentuated by psychosocial factors (39).
Whatever the case, it has been clear from this study’s results
that the brain cortex plays an important role in the integra-
tion of the vasovagal reflex, and this finding warrants further
investigation.
Quality of life and drug treatment for VVS. A rather
underestimated issue in vasovagal syndrome treatment,
which most of the times is not life-threatening, regards
these patients’ well-being during therapy. In this study, the
majority of patients were equally satisfied with the three
drugs tested, pertaining to not only the drugs’ therapeutic
efficacy and lack of side effects but also the patients’ personal
well-being. It was interesting to note that, although all
treatments improved their well-being, some patients were
not satisfied with propranolol treatment due to central side
effects, whereas a relatively small number of patients had a
feeling of “no drug” treatment with placebo. Hence, it seems
that certain patients need individualized therapy. This is in
keeping with the current concepts about VVS, which seem
to be the final clinical expression of different multiple
conditions that are still poorly characterized (1). In this
respect, quality-of-life issues should be taken into account
to individually optimize treatment.
Study limitations. The patients’ assessment periods were
relatively short (three months). However, a balance was
achieved by the high rate of symptoms before study inclu-
sion. Despite the small number of study patients, a massive
reduction in symptoms was observed during follow-up,
offering available discriminative power to the test used for
statistical evaluation. The present study did not systemati-
cally assess quality of life. In the future, more sophisticated
measures of this should be used.
CONCLUSIONS
Lipophilic and hydrophilic beta-blockers and placebo are
equally effective treatments in VVS, as demonstrated by the
reduction in the recurrence of syncope and presyncope, as
well as by improvement in the patients’ well-being. The
results of the present study favor the view that: 1) lipophilia
and, hence, central nervous system action, do not add to the
therapeutic efficacy of beta-blockade; and 2) cortical regions
acted upon by placebo (and possibly by patient reassure-
ment) are important in the integration of the vasovagal
reflex. Individualized selection of the ideal drug, as assessed
by a combination of its efficacy, lack of side effects and the
patient’s well-being, is sometimes warranted.
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